Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00897741|
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : February 11, 2014
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study uses gene expression profiling to compare primary tumor cells with metastatic tumor cells in patients with metastatic pancreatic cancer.
|Condition or disease||Intervention/treatment|
|Pancreatic Cancer||Genetic: microarray analysis Other: laboratory biomarker analysis|
- Compare the gene expression profiles of pancreatic cancer cells from the primary and metastatic sites in patients with metastatic pancreatic cancer.
- Characterize the function of the differentially upregulated and downregulated genes identified by comparing the gene expression profiles of primary and metastatic cells in these patients.
OUTLINE: Fresh biopsy samples are collected for gene expression profiling and other biomarker/laboratory analyses.
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Gene Expression Profiles in Primary and Metastatic Pancreatic Cancer|
|Study Start Date :||December 2004|
|Actual Primary Completion Date :||May 2008|
|Actual Study Completion Date :||March 2009|
- Gene expression profiles [ Time Frame: at time of biopsy ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00897741
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201|
|Study Chair:||Philip A. Philip, MD, PhD, FRCP||Barbara Ann Karmanos Cancer Institute|